NEW YORK (GenomeWeb) – Transgenomic announced today that it has signed an agreement for its ICE-COLD PCR technology with Canadian laboratory services LifeLabs.

Under the terms of the three-year deal, LifeLabs will have a non-exclusive license to the technology and use it in its mutation enrichment platform for cancer testing. The renewable agreement, Transgenomic said, allows LifeLab to benefit from technology improvements and additional product launches during its term.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Sep
20

This webinar will discuss how next-generation sequencing (NGS) can help clinical research labs and pathologists save time, money, and samples compared to single-analyte oncology research assays.

Sep
21

This webinar will demonstrate a new approach that combines precise FFPE tumor isolation with extraction-free DNA/RNA library preparation to minimize material losses and reduce the amount of tissue input required for NGS analysis.

Sep
27

This webinar will present an in-depth look at how Memorial Sloan Kettering Cancer Center has developed and implemented a next-generation sequencing panel for mutational tumor profiling of advanced cancer patients.

Oct
12
Sponsored by
PierianDx

This webinar will be a roundtable discussion on the adoption of a commercial gene panel for tumor profiling at several leading US cancer centers.